Anicura joins Mars Petcare
Anicura joins Mars Petcare https://doc4pets.de/wp-content/themes/corpus/images/empty/thumbnail.jpg 150 150Sven Jan Arndthttps://secure.gravatar.com/avatar/fef64081df258be6f19e1e0033636b82?s=96&d=mm&r=gWhat reads so harmlessly has immense significance for our industry. While Swedish financial investors disguised themselves as long-term investors with the will to do nothing but good for pets, the mask is now finally falling. After less than 8 years in the market, the financial investors have sold to the Mars Group, one of the largest groups in the food and pet industry besides Nestle.
About Mars Petcare from your own press release:
"These include PEDIGREE® , WHISKAS® , ROYAL CANIN® , NUTRO™, GREENIES™, SHEBA® , CESAR® , IAMS™ and EUKANUBA™ as well as theWALTHAM Centre for Pet Nutrition, which has been advancing scientific research into pet nutrition and health for more than 50 years. Mars Petcare is also the world's largest service provider for veterinary medicine with a network of more than 2,000 veterinary clinics, including BANFIELD™, BLUEPEARL™, PET PARTNERS™ and VCA™. …“
A tendency to monopolize an entire market seems clear if you look at this list.
Der komplette deutsche Pressetext ist hier zu finden: 180611-anicura-schliesst-sich-mars-petcare-an
What does this mean for the veterinary industry?
First of all, the wind that has previously prevailed at Anicura will probably stiffen even more and be trimmed even more in the direction of profit and yield optimization. A Mars has high profit targets and has already attracted attention in the past with one or two scandals(scandal about plastic wedges in chocolate bars etc.).
On the other hand, veterinarians willing to sell should in future better consider to whom they sell. Because the other colleagues on the market such as Evidensia etc. are also profit-oriented financial investors. That these also have an exit in mind in the long term seems obvious.
So if you want to continue to provide your services seriously in the future, free from the pressure of sales targets or return expectations of external financial investors, we think you should carefully consider whether the praised advantages cannot be achieved in any other way and whether the disadvantages even outweigh them.
